1329 related articles for article (PubMed ID: 18559696)
21. Aliskiren: an oral direct renin inhibitor for the treatment of hypertension.
Sanoski CA
Pharmacotherapy; 2009 Feb; 29(2):193-212. PubMed ID: 19170589
[TBL] [Abstract][Full Text] [Related]
22. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
[TBL] [Abstract][Full Text] [Related]
23. Enalapril and the kidney: renal vasodilation and natriuresis due to the inhibition of angiotensin II formation.
Navis GJ; de Zeeuw D; de Jong PE
J Cardiovasc Pharmacol; 1986; 8 Suppl 1():S30-4. PubMed ID: 2422491
[TBL] [Abstract][Full Text] [Related]
24. Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension.
Azizi M; Guyene TT; Chatellier G; Ménard J
J Hypertens; 1994 Apr; 12(4):419-27. PubMed ID: 8064166
[TBL] [Abstract][Full Text] [Related]
25. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels.
Komine N; Khang S; Wead LM; Blantz RC; Gabbai FB
Am J Kidney Dis; 2002 Jan; 39(1):159-64. PubMed ID: 11774115
[TBL] [Abstract][Full Text] [Related]
26. Aliskiren: clinical experience and future perspectives of renin inhibition.
Sureshkumar KK; Vasudevan S; Marcus RJ; Hussain SM; McGill RL
Expert Opin Pharmacother; 2008 Apr; 9(5):825-37. PubMed ID: 18345958
[TBL] [Abstract][Full Text] [Related]
27. The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension.
Gradman AH; Traub D
Rev Cardiovasc Med; 2007; 8 Suppl 2():S22-30. PubMed ID: 17401313
[TBL] [Abstract][Full Text] [Related]
28. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
[TBL] [Abstract][Full Text] [Related]
29. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.
Andersen K; Weinberger MH; Egan B; Constance CM; Ali MA; Jin J; Keefe DL
J Hypertens; 2008 Mar; 26(3):589-99. PubMed ID: 18300872
[TBL] [Abstract][Full Text] [Related]
30. Enhanced sodium retention after acute nitric oxide blockade in mildly sodium loaded patients with essential hypertension.
Bech JN; Nielsen EH; Pedersen RS; Svendsen KB; Pedersen EB
Am J Hypertens; 2007 Mar; 20(3):287-95. PubMed ID: 17324742
[TBL] [Abstract][Full Text] [Related]
31. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
[TBL] [Abstract][Full Text] [Related]
32. Cardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program.
Lee HY; Oh BH
Expert Rev Cardiovasc Ther; 2009 Mar; 7(3):251-7. PubMed ID: 19296761
[TBL] [Abstract][Full Text] [Related]
33. Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects.
Burnier M; Brunner HR
Exp Nephrol; 1996; 4 Suppl 1():41-6. PubMed ID: 9001896
[TBL] [Abstract][Full Text] [Related]
34. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.
van Esch JH; Moltzer E; van Veghel R; Garrelds IM; Leijten F; Bouhuizen AM; Danser AH
J Hypertens; 2010 Oct; 28(10):2145-55. PubMed ID: 20625318
[TBL] [Abstract][Full Text] [Related]
35. Different reactivity to angiotensin II of peripheral and renal arteries in spontaneously hypertensive rats: effect of acute and chronic angiotensin converting enzyme inhibition.
Guidi E; Hollenberg NK
J Hypertens Suppl; 1986 Dec; 4(6):S480-2. PubMed ID: 11538668
[TBL] [Abstract][Full Text] [Related]
36. Is l-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature?
Schlaich MP; Jacobi J; John S; Delles C; Fleischmann I; Schmieder RE
Clin Sci (Lond); 2000 Oct; 99(4):293-302. PubMed ID: 10995594
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic/pharmacodynamic modeling of renin biomarkers in subjects treated with the renin inhibitor aliskiren.
Hong Y; Dingemanse J; Mager DE
Clin Pharmacol Ther; 2008 Jul; 84(1):136-43. PubMed ID: 18288088
[TBL] [Abstract][Full Text] [Related]
38. The acute renal actions of angiotensin converting enzyme inhibitors in the sodium-depleted conscious primate are mediated by inhibition of the renin-angiotensin system.
Humke U; Levens N; Wood J; Hofbauer K
J Pharmacol Exp Ther; 1992 Jan; 260(1):29-35. PubMed ID: 1309874
[TBL] [Abstract][Full Text] [Related]
39. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
[TBL] [Abstract][Full Text] [Related]
40. Pharmacologic interruption of the renin-angiotensin system and the kidney: differential responses to angiotensin-converting enzyme and renin inhibition.
Hollenberg NK
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S239-42. PubMed ID: 9892171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
